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A DOG’S TALE



The Veterinary Clinical
Investigations Center in Action
BY ELLEN LYON

Dr. Dorothy Cimino
Brown with Rocky, a past
participant in a VCIC pain
management study.
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L

ast summer Jeff Gillman noticed that his German
shepherd mix, Reuben, had lost a lot of weight.
After examining the dog, Reuben’s veterinarian told
Gillman to take him to a specialty animal hospital
right away. Gillman knew just where to go: Penn Vet’s
Ryan Hospital. “It’s the best emergency hospital,” he said.
Penn veterinarians removed Reuben’s spleen and
did a biopsy. Back came the dreaded diagnosis of
hemangiosarcoma, an aggressive cancer of the blood vessels,
and a grim prognosis of two-to-four months without
treatment and four-to-six months with chemotherapy.
“I was crushed, absolutely crushed,” Gillman said. A
dozen years earlier he had picked Reuben from a litter
of puppies at a farmers market in Santa Cruz. Reuben
rode in Gillman’s backpack, with his paws hanging out, as
they traveled the West Coast that summer after Gillman’s
freshman year of college. “At this point, he’s one of my
oldest friends,” Gillman said.
So Gillman leapt at the opportunity when the
veterinarians at Ryan Hospital told him about a study
Reuben could participate in through Penn Vet’s Veterinary
Clinical Investigations Center (VCIC). The study compares
the effects of the traditional Chinese medicine I’m-Yunity, a
compound derived from the Coriolus versicolor mushroom,
to standard chemotherapy treatment on survival time and
quality of life for dogs with splenic hemangiosarcoma.
Dr. Dorothy Cimino
Brown is director
of the VCIC and a
board-certified small
animal surgeon. In a
published study, Brown
and Jennifer Reetz, an
attending radiologist,
showed that dogs with
hemangiosarcoma that
were treated with I’mYunity had the longest
survival time reported
for dogs with the
disease. The VCIC is

collaborating on
the study with a
Chinese company
that seeks to
apply the Western
scientific method to
Eastern medicine.
Reuben’s study
is divided into three
Dr. Erica Himmelreich,
groups. One group
oncology research
is being treated with
intern, with Reuben.
chemotherapy alone.
A second group is
being treated with I’m-Yunity alone. And a third group
is being treated with both chemotherapy and I’m-Yunity.
Gillman doesn’t know which group Reuben is in, but he
believes it’s one of the groups getting I’m-Yunity. It has
been a year since Reuben’s diagnosis, and he’s still going
strong.
The VCIC was created in 2005 to support Penn Vet
investigators engaged in clinical research and to coordinate
clinical trials of novel approaches for treating, managing, and
preventing disease in animals.
“I love research and solving problems to make life
better,” said Penn Vet Dean Joan Hendricks, who founded
the VCIC. Section chief for critical care at Ryan Hospital
at the time, she envisioned a research center where
“our animal patients might be able to get access to new
treatments and interventions,” often at less or no expense
to the client. And the infrastructure would assist Penn Vet
investigators with monitoring their subjects and meeting
regulatory requirements, she said.
The center would translate research on novel treatments
that began in lab animal studies to trials in companion
animals that develop many of the same diseases as people.
The VCIC’s first clinical trial was sponsored by Pfizer
Animal Health, the result of an idea pitched to them by
Hendricks. After nearly two years of negotiations, Hendricks
felt confident that the VCIC model would work. “We
always made sure there was something we could publish, no
matter what,” she noted.

“While all VCIC studies have direct applications to animal health,
about half the trials running now have sponsors that are ultimately
interested in application of the results to human health as well.”
— Dr. Dorothy Cimino Brown, Director of Penn Vet’s Veterinary Clinical Investigations Center
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Clinical research
nurse Rene Newman,
CVT, prepares a
sedated dog for an
elbow injection in a
stem cell study.

But Hendricks worried about the clients. Would they
understand the risks and the lack of guarantees for their
beloved pets? To ensure that clients do, VCIC staff conducts
a rigorous informed-consent process, and Hendricks has
been overwhelmed by their altruistic attitude. “It’s very
important to them that their pet helps another animal. They
go into it with their eyes open,” she said.
In addition, clients’ pets are “getting access to potential
interventions that they wouldn’t otherwise have access to
anywhere else,” Brown noted. In post-study surveys, clients
routinely say they appreciate the frequent contact they have
with the clinical trials nurses, including being given cell
phone numbers if they have questions or problems.
Gillman sounded pleased about the care Reuben receives
as part of the I’m-Yunity study. “He goes there and he has a
nurse. They treat him like he’s the only [patient],” Gillman
said.
More than three-fourths of clients participating in VCIC
studies are new to Penn Vet, Brown noted. At the end of
their studies, more than 90 percent say they would consider
returning.
The VCIC began with one principal investigator
(Brown), one veterinary nurse, and one study. It has grown
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to include the participation of dozens of investigators aided
by five veterinary clinical trials nurses.
Brown is responsible for one of the VCIC’s biggest
successes so far. She collaborated with Dr. Michael Iadarola
to study resiniferatoxin (RTX)—a naturally occurring
substance from a Moroccan cactus-like succulent plant—as
a potential treatment for chronic pain from canine bone
cancer. They gave dogs one injection of RTX into the fluid
around the spinal cord.
“The effect was stunning,” said Iadarola, a senior research
scientist at the National Institutes of Health. An article from
the May-June 2006 NIH Catalyst noted that: “All of the
dogs experienced significant pain relief that lasted for the
rest of their lives.”
Iadarola said such results with dogs provided a
“tremendous incentive” to move to human trials—the first
of which, involving patients with advanced cancer, is going
on now. RTX initially had been tested on rodents. “To go
directly from the rat to the human was a pretty big step,” he
said. Often such large leaps in drug testing result in a high
failure rate, Brown said, because the pre-clinical models
don’t mimic what goes on with people, and the disease is
artificially induced in the rodents.

ANIMALS SOUGHT FOR
VCIC CLINICAL TRIALS
Plant-Derived Supplements to
Boost Quality of Life in Geriatric Dogs
ELIGIBILITY: 10 years of age or older; not on any medication
BENEFITS: Study visits; blood work; $100 gift card on
completion of all study visits

Stem Cell Therapy for Dogs
with Elbow Dysplasia (FMCP form)
ELIGIBILITY: Diagnosis of fragmented medial coronoid
processes (FMCPs); younger than 2 years; weighs at least
33 pounds; clinical signs of arthritis
BENEFITS: Orthopedic exams; arthroscopic surgery and
removal of FMCPs; adjunctive stem cell or hyaluronic acid
therapy; follow-up care for one year

Palladia® for Dogs with
Appendicular Osteosarcoma
This trial is an option for owners who decline
chemotherapy, but want to try to control cancer
using oral medication at home.
ELIGIBILITY: Diagnosis of OSA; no metastasis to lungs
BENEFITS: Study-related costs; blood work and chest
radiographs; study drug and supportive medications

Comparison of Three New Chemotherapy
Drugs for Dogs with Lymphoma
ELIGIBILITY: Diagnosis of multi-centric lymphoma; weighs
at least 33 pounds; not receiving treatment for lymphoma
BENEFITS: Study visits and treatments; $1,000 towards
future care at Penn Vet
For more information on these and other studies,
visit www.vet.upenn.edu/vcic, call 215-573-0302,
or email vcic@vet.upenn.edu
Follow VCIC on Twitter @PennVet_VCIC

But when testing makes a stop in between
with companion animals, they “share the same
environment [with humans]. Many of the same risk
factors are going to be present as in people,” Brown
said. That makes the results more likely to be
replicable in humans. As Hendricks noted, the loss
of laboratory conditions “makes the science much
harder and much, much closer to reality.”
Studies with companion animals also allow
researchers to better gauge a drug’s possible side
effects. Owners can assess their dog’s pain, bladder
and bowel function, and activity level at home, and
notice any personality changes, Iadarola said.
It is a natural progression for the only veterinary
school in the country founded through a medical
school to also be the first to create a research facility
dedicated to translational research. The VCIC
exemplifies Penn Vet’s longstanding commitment
to One Health, which aims to advance health care
and well-being for animals and humans through
collaborative, interdisciplinary practices. The VCIC’s
goal is to get cutting-edge therapies to patients—
both animal and human—as efficiently as possible.
The VCIC has completed 46 studies, according
to Managing Director Michael DiGregorio.
Currently, 19 trials involving 18 faculty members are
underway, and another six trials are being planned.
While all VCIC studies have applications to animal
health, about half the trials running now have
sponsors that are ultimately interested in application
of the results to human health as well, Brown said.
Industry representatives, government
organizations, individuals, and foundations fund
the VCIC’s studies, DiGregorio said. Subjects are
recruited using traditional advertising, web and
social media, and through the network of more than
3,000 veterinary practices that refer the pets that
make the 30,000 visits to Ryan Hospital each year.
The VCIC recently finished its first large animal
study at New Bolton Center, which looked at a
novel estrus synchronization protocol in cows.
Another large animal trial—studying risk assessment
of cross-contamination among different species
including cows, goats, and sheep—is underway,
DiGregorio said.
Gillman finds universal and personal value in the
VCIC’s work. Reuben’s participation in a study
may lead to better prognoses for dogs with the same
kind of cancer in the future. “I’m glad that Reuben
gets to help. We take that seriously,” Gillman said.
“I think the study has been a blessing. I don’t think
that he would have lasted a year. The study has
allowed me to really cherish and enjoy him.”
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